Tianjin Pharmaceutical Da Ren Tang Confirms Business Validity of Controlling Shareholder's Finance Unit

MT Newswires08-15

Tianjin Pharmaceutical Da Ren Tang (SGX:T14, SHA:600329) confirmed that its latest risk assessment report on Tianjin Pharmaceutical Group Finance is accurate and complete, according to a Wednesday filing on the Singapore Exchange.

This update follows SSE regulations requiring biannual risk assessments for transactions with related finance companies.

Tianjin Pharmaceutical Group Finance, a unit of Tianjin Pharmaceutical Holdings, provides financial services including settlement, intermediary, deposit, and credit services.

The assessment confirms that Tianjin Pharmaceutical Group Finance adheres to regulatory standards with robust risk management, including liquidity, credit, and settlement controls.

Price (SGD): S$2.18, Change: S$-0.05, Percent Change: -2.24%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459465532?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-15 10:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2459465532","market":"sg","top_or_hot":-1,"title":"Tianjin Pharmaceutical Da Ren Tang Confirms Business Validity of Controlling Shareholder's Finance Unit","media":"MT Newswires","content":"<html><body><p> Tianjin Pharmaceutical Da Ren Tang (SGX:T14, SHA:600329) confirmed that its latest risk assessment report on Tianjin Pharmaceutical Group Finance is accurate and complete, according to a Wednesday filing on the Singapore Exchange.</p><p>This update follows SSE regulations requiring biannual risk assessments for transactions with related finance companies.</p><p>Tianjin Pharmaceutical Group Finance, a unit of Tianjin Pharmaceutical Holdings, provides financial services including settlement, intermediary, deposit, and credit services.</p><p>The assessment confirms that Tianjin Pharmaceutical Group Finance adheres to regulatory standards with robust risk management, including liquidity, credit, and settlement controls.</p><p>Price (SGD): S$2.18, Change: S$-0.05, Percent Change: -2.24%</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin Pharmaceutical Da Ren Tang Confirms Business Validity of Controlling Shareholder's Finance Unit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin Pharmaceutical Da Ren Tang Confirms Business Validity of Controlling Shareholder's Finance Unit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-15 10:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tianjin Pharmaceutical Da Ren Tang (SGX:T14, SHA:600329) confirmed that its latest risk assessment report on Tianjin Pharmaceutical Group Finance is accurate and complete, according to a Wednesday ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0164","symbol_name":"国企混改","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2459465532","we_media_id":"1060499803","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459465532","pubTimestamp":1723687860,"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1060499803","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tianjin Pharmaceutical Da Ren Tang  confirmed that its latest risk assessment report on Tianjin Pharmaceutical Group Finance is accurate and complete, according to a Wednesday filing on the Singapore Exchange.This update follows SSE regulations requiring biannual risk assessments for transactions with related finance companies.Tianjin Pharmaceutical Group Finance, a unit of Tianjin Pharmaceutical Holdings, provides financial services including settlement, intermediary, deposit, and credit services.The assessment confirms that Tianjin Pharmaceutical Group Finance adheres to regulatory standards with robust risk management, including liquidity, credit, and settlement controls.Price : S$2.18, Change: S$-0.05, Percent Change: -2.24%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600329":"达仁堂","BK0164":"国企混改","BK6079":"制药","BK0188":"融资融券","BK0028":"国家队","BK6506":"制药与医学研究概念","T14.SI":"达仁堂","BK0060":"抗癌","BK0239":"医药制造"},"translate_title":"天津医药大仁堂确认控股股东财务单位业务有效性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600329":0.9,"T14.SI":0.9},"content_text":"Tianjin Pharmaceutical Da Ren Tang (SGX:T14, SHA:600329) confirmed that its latest risk assessment report on Tianjin Pharmaceutical Group Finance is accurate and complete, according to a Wednesday filing on the Singapore Exchange.This update follows SSE regulations requiring biannual risk assessments for transactions with related finance companies.Tianjin Pharmaceutical Group Finance, a unit of Tianjin Pharmaceutical Holdings, provides financial services including settlement, intermediary, deposit, and credit services.The assessment confirms that Tianjin Pharmaceutical Group Finance adheres to regulatory standards with robust risk management, including liquidity, credit, and settlement controls.Price (SGD): S$2.18, Change: S$-0.05, Percent Change: -2.24%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459465532"}